CAR-NK Cell Therapy for Advanced Biliary Tract Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to target cancer cells in advanced biliary tract cancers—including bile duct and gallbladder cancers. The cells are engineered to recognize and attack cancer cells that have specific markers (HER2 and CEA), and this approach may help patients whose cancer has progressed after standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed diagnosis of advanced (unresectable, recurrent, or metastatic) biliary tract cancer—intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, or gallbladder cancer
- Cancer has progressed after at least one prior chemotherapy regimen containing gemcitabine and platinum
- Tumor testing confirms HER2 and CEA positivity (specific protein markers on cancer cells)
- At least one measurable tumor lesion on imaging that can be tracked during the trial
- Good overall health status and adequate organ function (heart, lungs, liver, kidneys, bone marrow)
- No untreated or unstable brain metastases; no active, uncontrolled infections; resolved or stable biliary drainage
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy made from natural killer (NK) cells that are engineered to attack two targets (GPC3 and B7-H3) found on liver cancer cells. It may be an option for people with advanced liver cancer who have already tried standard treatments.
This trial tests whether specially engineered NK cells can find and attack your type of cancer. It is for people with advanced solid tumors that haven't responded to standard treatments.
This trial tests a new type of cell therapy (CAR-NK cells) designed to attack gastric and esophageal junction cancers that have specific markers on their surface. The cells are engineered to recognize two targets on your cancer cells, which may help your immune system fight the cancer more effectively.
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets specific proteins on breast cancer cells. It's for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments or can't take them.
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two markers on breast cancer cells. It is for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments and need new options.
This trial tests a new treatment using modified natural killer cells (CAR-NK) that target two specific proteins found on your cancer cells. It is for people with advanced colorectal cancer who have tried standard treatments without success.
Hear when a new Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.